Source: International Congress 2017 – Lung cancer: important scientific reports from endoscopists and thoracic surgeons
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
F. Verdu Rivera (Spain). Systemic inflamation and prognosis in lung cancer stage I-II. 4285

Member's Comments

No comment yet.

Related content which might interest you: Treatment of non-microcelular lung cancer in its advanced stage Source: Annual Congress 2008 - Treatment of thoracic tumours Year: 2008 Effect of cardiovascular comorbidities on the survival patients with stage I and II non-small-cell lung cancer Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 Management of locally advanced nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 260–270 Year: 2009 Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 269s Year: 2002 Age and stage at presentation in lung cancer Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 Analysis of prognostic factors in patients with stage IIIB, IV non-small cell lung cancer Source: Annual Congress 2010 - Staging of lung cancer Year: 2010 Systemic treatment of advanced NSCLC Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer Year: 2007 Current neoadjuvant/adjuvant treatment for advanced stage lung cancer Source: International Congress 2014 – PG19 Surgery for advanced stage lung cancer Year: 2014 Disease relapse in surgically and conservatively treated patients with stage I-II of non-small cell lung cancer Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series Year: 2010 Management of stage I and II nonsmall cell lung cancer Source: Eur Respir J 2017; 49(1): 1600764; DOI: 10.1183/13993003.00764-2016 Year: 2017 Treatment of early (stage I/II) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 Clinicopathologic features of patients with non-small cell lung cancer and chronic obstructive pulmonary disease undergoing lung cancer surgery Source: Virtual Congress 2020 – Localised non-small cell lung cancer Year: 2020 Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019 Prognostic factors in resected pathological N1-stage II nonsmall cell lung cancer Source: Eur Respir J 2013; 41: 649-655 Year: 2013 A retrospective analysis of risk factors for Durvalumab related interstitial lung disease after chemoradiotherapy in Stage III NSCLC Source: Virtual Congress 2020 – Localised non-small cell lung cancer Year: 2020 Comparative evaluation of resectability, postoperative morbidity and mediastinal downstaging after cisplatin-based chemoinduction versus radiochemoinduction for stage III non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 214s Year: 2003 Surfactant protein-D level as a predictor of prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer Source: International Congress 2016 – Orphan diseases I Year: 2016 Survival of patients operated for stage I non-small-cell lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 Carboplatin-paclitaxel alone or with bevacizumab in stage III-IV lung adenocarcinoma Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011 A study on chemotherapy induced interstitial lung disease in patients with unresectable non-small cell lung cancer complicated by combined pulmonary fibrosis and emphysema Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012